Genentech's Actemra gains FDA approval for rheumatoid arthritis

01/10/2010 | San Francisco Chronicle

The FDA approved Genentech's Actemra, the only rheumatoid arthritis drug that targets the interleukin-6 protein, which plays a role in joint inflammation. The treatment is expected to benefit patients who do not respond to Remicade, Humira or Enbrel, which target an inflammatory protein called tumor necrosis factor-alpha.

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC